159 related articles for article (PubMed ID: 3285796)
21. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
22. [Quantitative determination of human bone marrow T cells following in vitro depletion by Campath-1 monoclonal antibody].
Irlé C; Kaestli M; Chapuis B; Jeannet M
Schweiz Med Wochenschr; 1985 Oct; 115(43):1517-8. PubMed ID: 3909385
[TBL] [Abstract][Full Text] [Related]
23. Depletion of T-lymphocytes in donor marrow with pan-T monoclonal antibodies and complement for prevention of acute graft-versus-host disease: a pilot study on 29 patients.
Herve P
J Natl Cancer Inst; 1986 Jun; 76(6):1311-6. PubMed ID: 3520074
[TBL] [Abstract][Full Text] [Related]
24. Graft-versus-host disease in allogeneic bone marrow transplantation: the role of monoclonal antibodies in prevention and treatment.
Hiscott A; McLellan DS
Br J Biomed Sci; 2000; 57(2):163-9. PubMed ID: 10912294
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance.
Cobbold SP; Martin G; Qin S; Waldmann H
Nature; 1986 Sep 11-17; 323(6084):164-6. PubMed ID: 3528866
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic bone marrow transplantation in the treatment of hematologic diseases.
Yee GC; McGuire TR
Clin Pharm; 1985; 4(2):149-60. PubMed ID: 3886273
[TBL] [Abstract][Full Text] [Related]
27. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM
Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439
[TBL] [Abstract][Full Text] [Related]
28. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
[TBL] [Abstract][Full Text] [Related]
29. T-cell depletion and allogeneic bone marrow transplantation.
O'Reilly RJ
Semin Hematol; 1992 Apr; 29(2 Suppl 1):20-6. PubMed ID: 1615341
[No Abstract] [Full Text] [Related]
30. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.
Apperley JF; Jones L; Hale G; Waldmann H; Hows J; Rombos Y; Tsatalas C; Marcus RE; Goolden AW; Gordon-Smith EC
Bone Marrow Transplant; 1986 May; 1(1):53-66. PubMed ID: 3332120
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
[TBL] [Abstract][Full Text] [Related]
32. Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation.
Gowing H; Braakman E; Hagenbeek A; Lawler M; McCann SR; Pamphilon DH; Martens AC
Bone Marrow Transplant; 1998 Apr; 21(8):801-7. PubMed ID: 9603404
[TBL] [Abstract][Full Text] [Related]
33. Comparison of three techniques for the ex vivo elimination of T cells from human bone marrow.
Blazar BR; Quinones RR; Heinitz KJ; Sevenich EA; Filipovich AH
Exp Hematol; 1985 Feb; 13(2):123-8. PubMed ID: 3882442
[TBL] [Abstract][Full Text] [Related]
34. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
35. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
36. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
Soiffer RJ; Freedman AS; Neuberg D; Fisher DC; Alyea EP; Gribben J; Schlossman RL; Bartlett-Pandite L; Kuhlman C; Murray C; Freeman A; Mauch P; Anderson KC; Nadler LM; Ritz J
Bone Marrow Transplant; 1998 Jun; 21(12):1177-81. PubMed ID: 9674848
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb.
Patel NC; Chinen J; Rosenblatt HM; Hanson IC; Brown BS; Paul ME; Abramson SL; Ritz J; Shearer WT
J Allergy Clin Immunol; 2008 Dec; 122(6):1185-93. PubMed ID: 19084111
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders.
Slavin S; Or R; Naparstek E; Weiss L; Mumcuoglu M; Weshler Z; Brautbar H; Cividalli G; Glikson M; Hale G
Transplant Proc; 1987 Feb; 19(1 Pt 3):2614-5. PubMed ID: 3274569
[No Abstract] [Full Text] [Related]
39. Leukaemia and lymphoma treatment with autologous bone marrow transplantation: preclinical studies.
Janossy G; Campana D; Amlot PL
Cancer Detect Prev; 1988; 12(1-6):597-604. PubMed ID: 3052841
[TBL] [Abstract][Full Text] [Related]
40. [Contribution of bone marrow transplantation to the treatment of children with leukemia].
Vossen JM; van Leeuwen EF; van 't Veer-Korthof ET; Slaper-Cortenbach CM; van den Berg H; Gerritsen EJ; Hermans J; Weening RS
Tijdschr Kindergeneeskd; 1988 Apr; 56(2):73-82. PubMed ID: 3287686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
